SWOT Analysis for Fermenta Biotech Ltd.

Add SWOT widget to your site/app

MACD Crossover Above Signal Line
Positive Breakout Third Resistance ( LTP > R3)
Growth Factor Screener: Rising returns on equity (ROE), Momentum, and Earnings Yield
Benjamin Graham Value Screen
Price crossing above SMA20 today, and greater than SMA5
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
Strong Performer, Under Radar Stocks (DVM)
Undervalued Growth Stocks
Jim Slater's Zulu Principle (Discover Growth Stocks)
Relative Outperformance versus Industry over 1 Month
Relative Outperformance versus Industry over 1 Year
Growth Stars: Strongest Annual EPS Performers
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Dividend yield greater than sector dividend yield
High Momentum Scores (Technical Scores greater than 50)
Good quarterly growth in the recent results
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Companies with Low Debt
Annual Net Profits improving for last 2 years
Companies with Zero Promoter Pledge
Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
Stock with Low PE (PE < = 10)
RSI indicating price strength
MACD crossed above signal line previous end of day
Top Gainers
Volume Shockers
Stocks Outperforming their Industry Price Change in the Quarter

MACD Crossover Above Signal Line

Positive Breakout Third Resistance ( LTP > R3)

Growth Factor Screener: Rising returns on equity (ROE), Momentum, and Earnings Yield

Benjamin Graham Value Screen

Price crossing above SMA20 today, and greater than SMA5

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE

Strong Performer, Under Radar Stocks (DVM)

Undervalued Growth Stocks

Jim Slater's Zulu Principle (Discover Growth Stocks)

Relative Outperformance versus Industry over 1 Month

Relative Outperformance versus Industry over 1 Year

Growth Stars: Strongest Annual EPS Performers

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Dividend yield greater than sector dividend yield

High Momentum Scores (Technical Scores greater than 50)

Good quarterly growth in the recent results

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Companies with Low Debt

Annual Net Profits improving for last 2 years

Companies with Zero Promoter Pledge

Recent Results : Growth in Operating Profit with increase in operating margins (YoY)

Stock with Low PE (PE < = 10)

RSI indicating price strength

MACD crossed above signal line previous end of day

Top Gainers

Volume Shockers

Stocks Outperforming their Industry Price Change in the Quarter

Companies with growing costs YoY for long term projects
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Declining Revenue every quarter for the past 2 quarters
Declining profits every quarter for the past 2 quarters
Declining Net Cash Flow : Companies not able to generate net cash
Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)
Increasing Trend in Non-Core Income

Companies with growing costs YoY for long term projects

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Declining Revenue every quarter for the past 2 quarters

Declining profits every quarter for the past 2 quarters

Declining Net Cash Flow : Companies not able to generate net cash

Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)

Increasing Trend in Non-Core Income

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
Declining Net Cash Flow and Cash from Operating Activity for last 2 years
Decline in Net Profit with falling Profit Margin (QoQ)

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Declining Net Cash Flow and Cash from Operating Activity for last 2 years

Decline in Net Profit with falling Profit Margin (QoQ)

Fermenta Biotech Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Fermenta Biotech Ltd. has 34 Strengths, 7 Weaknesses, 0 Opportunities and 0 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential